Autonomous Therapeutics and Mink Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Written By Ariel Weinberger

This collaboration will leverage Autonomous Therapeutics’ precision encrypted RNA™ (encRNA) technology and MiNK’s innovative iNKT cell therapies, MiNK-215 and agenT-797. The companies will leverage these technologies with the goal of effectively and precisely targeting difficult-to-treat metastatic solid tumors.

Ariel Weinberger
Next

Autonomous CEO, Dr. Ariel Weinberger, serves on keynote panel at World Vaccine & Immunotherapy Congress